News and Trends 24 Jul 2020
Swiss Company Raises €23M to Smash Cancer with Bacteria
Basel-based T3 Pharmaceuticals has closed its third financing round, worth over €23.3M (CHF 25M), to develop a bacterial cancer therapy. Since T3 Pharma was spun off from the University of Basel in 2015, the firm has raised €37M (CHF 40M). The fundraiser included investors such as Boehringer Ingelheim Venture Fund, Reference Capital, and Wille Finance. […]